Ionis Pharmaceuticals (IONS) Reports Strong 1Q, Eplontersen PN Data Soon - BMO Capital

BMO Capital analyst Do Kim reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the company reported 1Q revenue / non-GAAP EPS of $142mm / $(0.27) which beat
cons. $123mm / $(0.48).

The analyst stated "Strong 1Q driven by $40mm BIIB milestones for neuro programs and higher licensing revenue, while Spinraza performed well and opex was lower. Guidance reaffirmed and seems very achievable. Key focus on Eplontersen with ATTR-PN data midyear, and IONS explained rationale for extending CM study (partner AZN) to increase patients/duration that will provide even more robust data and potentially position drug better in large/competitive market."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $38.05 yesterday.

You May Also Be Interested In

• Infracommerce CXAAS SA (IFCM3:BZ) PT Lowered to BRL7 at Credit Suisse
• BHP (BHP:LN) (BHP) PT Lowered to GBP25.10 at JPMorgan
• Nordea Bank Abp (NDA:SS) (NRDBY) PT Lowered to EUR9.20 at Credit Suisse